Activating Compound | Comment | Organism | Structure |
---|---|---|---|
p35 | - |
Homo sapiens |
Application | Comment | Organism |
---|---|---|
medicine | plays an important role in prostate cancer motility and metastasis, is important for spontaneous metastasis in vivo | Homo sapiens |
Cloned (Comment) | Organism |
---|---|
dominant-negative CDK5 mutant subcloned into a bidirectional vector expressing GFP in a Tet-Off system and expressed in AT6.3 cells, mice subcutaneous xenografts of AT6.3 cells expressing the dominant-negative CDK5 mutant | Homo sapiens |
Protein Variants | Comment | Organism |
---|---|---|
D144N | dominant-negative CDK5 mutant, results in a loss of motility of the cells through effects on the cytoskeleton, which correlates with dramatically lower invasive potential, leads to 79% reduction in the number of lung metastases per milligram of primary xenograft tumors | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
roscovitine | blocks the motility of prostate cancer cells in a wound healing assay | Homo sapiens | |
siRNA | blocks the motility of prostate cancer cells in a wound healing assay | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
DU-145 cell | CDK5 together with p35 | Homo sapiens | - |
LNCaP cell | CDK5 together with p35 | Homo sapiens | - |
additional information | CDK5 together with p35 present in AT6.3 cells, AT3.1 cells, MatLu cells and MatLyLu cells | Homo sapiens | - |
PC-3 cell | CDK5 together with p35 | Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
ATP + PKTPKKAKKL | - |
Homo sapiens | ADP + PKpTPKKAKKL | - |
? |
Synonyms | Comment | Organism |
---|---|---|
Cdk5 | - |
Homo sapiens |
cyclin-dependent kinase 5 | - |
Homo sapiens |